TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01181310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
Description: A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
Description: A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
Study: NCT02413866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction only
Description: Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep & calorie restriction
Description: Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
Study: NCT03230903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home telerehabilitation
Description: Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
Study: NCT04324099

Intervention type: OTHER
Intervention: neuroimaging session (with simultaneously acquired eye-tracking)
Description: neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
Study: NCT01181310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
Description: A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
Description: A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
Description: A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
Description: A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
Study: NCT00239356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
Study: NCT00109005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
Study: NCT01462968

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activated clotting time versus blood-heparin concentration
Description: Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated clotting time versus blood-heparin concentration
Description: Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
Study: NCT03854812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
Study: NCT00033111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill manufactured to mimic cabergoline 05mg tablet
Study: NCT02280486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1mg/d, up titrated 1mg if FPG \>6.1 mmol/L (110mg/dL) till 6 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1mg/d, up titrated 1mg if FPG \>6.1 mmol/L (110mg/dL) till 6 mg
Study: NCT00456885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exenatide
Description: 5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: 5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily injection of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice daily injection of placebo
Study: NCT00392834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV
Study: NCT00392834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV
Study: NCT03474497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: • A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered to the treatment lesion during the second cycle of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1-2 of cycle 2 and will not be repeated in future cycles.
Study: NCT03148561

Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
Study: NCT03652558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone application with the Ozonytron XL device
Description: An ozone generator (Ozonytron; Bionix, Munchen, Germany) with an KPX probe (CA Probe; Ozonytron, Bionix, Munchen, Germany) was used for OT. Topical gaseous ozone was applied into the periodontal pocket twice a week for 2 weeks based on the manufacturer's instructions. Ozone applications were at 75% power for 30 seconds (75 µg/ml). Ozone applications were performed by an experienced investigator. Ozone applications in the control side were simulated without starting the ozone generator
Study: NCT02828306

Intervention type: OTHER
Intervention: Patient Specific Implant
Description: Implantation of Patient Specific Implant
Study: NCT03257514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha lipoic acid drug (thioctic acid acid)
Description: Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo oral drug have the same shape of thiotacid tablet
Study: NCT01865240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal Denervation Catheter
Study: NCT03467880

Intervention type: OTHER
Intervention: Clinical Observation
Description: No treatment given but observation with IOS

Intervention type: OTHER
Intervention: Clinical Observation
Description: No treatment given but observation with IOS

Intervention type: OTHER
Intervention: Clinical Observation
Description: No treatment given but observation with IOS

Intervention type: OTHER
Intervention: Clinical Observation
Description: No treatment given but observation with IOS

Intervention type: OTHER
Intervention: Clinical Observation
Description: No treatment given but observation with IOS
Study: NCT00392834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine
Description: given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine
Description: given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: given IV
Study: NCT00579553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Progesterone
Description: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Progesterone
Description: Vaginal Progesterone: 100 mg vaginal suppository daily
Study: NCT03726658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241751
Description: AGN-241751 is supplied in tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241751
Description: AGN-241751 is supplied in tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241751
Description: AGN-241751 is supplied in tablet form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied in tablet form
Study: NCT00190229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study: NCT00412958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 25µg
Description: Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 75µg
Description: Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 125µg
Description: Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravitreal injection of placebo
Study: NCT02818764

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: 5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: 5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.

Intervention type: PROCEDURE
Intervention: Cerebral Spinal Fluid collection
Description: Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
Study: NCT02312011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-DMPKRx
Description: Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00081939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
Study: NCT00422669

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Dual-Chamber Pacemaker
Description: A Medtronic market-approved dual-chamber implantable pulse generator (IPG)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Dual-Chamber Pacemaker
Description: A Medtronic market-approved dual-chamber implantable pulse generator (IPG)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic SelectSecure 3830 Lead
Description: Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic SelectSecure 3830 Lead
Description: Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
Study: NCT03405155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00964600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP blockade
Description: 15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
Study: NCT02156752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Treatment is based on Acceptance and Commitment Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SR
Description: Treatment is based on Self-Regulation theory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WLO
Description: Treatment is based on cooking tips and demonstrations.
Study: NCT02818764

Intervention type: PROCEDURE
Intervention: Cerebral Spinal Fluid collection
Description: Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
Study: NCT04324099

Intervention type: OTHER
Intervention: Interpersonal Reactivity Index (IRI) (for children)
Description: The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales

Intervention type: OTHER
Intervention: Interpersonal Reactivity Index (IRI) (for children)
Description: The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales

Intervention type: OTHER
Intervention: Youth Psychopathic Traits Inventory (YPI) (for children)
Description: self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.

Intervention type: OTHER
Intervention: Youth Psychopathic Traits Inventory (YPI) (for children)
Description: self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.

Intervention type: OTHER
Intervention: Youth Psychopathic Traits Inventory (YPI) (for children)
Description: self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.

Intervention type: OTHER
Intervention: Reactive Proactive Questionnaire (RPQ) (for children)
Description: The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
Study: NCT02818764

Intervention type: DEVICE
Intervention: Electroencephalogram
Description: Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.

Intervention type: DEVICE
Intervention: Electroencephalogram
Description: Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.

Intervention type: DEVICE
Intervention: Cerebral blood flow and oxygen extraction fraction
Description: NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.

Intervention type: DEVICE
Intervention: Cerebral blood flow and oxygen extraction fraction
Description: NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
Study: NCT02290496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Insomnia (CBT-I)
Description: Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Hygiene (SH)
Description: Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
Study: NCT03897465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lomatuell Pro
Description: Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UrgoTul
Description: Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
Study: NCT01599065

Intervention type: OTHER
Intervention: Magnet or Off-On
Description: Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
Study: NCT00934830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: 1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
Study: NCT01754701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate iron
Description: Children who start 4 weeks of iron therapy on Day 0

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Delayed iron
Description: Children who start 4 weeks of iron therapy on Day 28
Study: NCT02478632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subjects do not receive study medication in this study 202094
Description: Participants do not receive study medication in this study 202094.
Study: NCT03065218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc sestamibi
Description: The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.